Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
propofol + valproate
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A clinically significant drug interaction where valproate increases blood levels of propofol through inhibition of propofol metabolism and increasing the proportion of protein-unbound free propofol in the blood. This interaction requires dose reduction of propofol when co-administered with valproate to prevent excessive sedation.
02
Targets
CYP2C9 (Cytochrome P450 family 2 subfamily C member 9)NaV (Voltage-gated sodium channels)UGT1A9 (UDP-glucuronosyltransferase 1A9)
Beyond the preview
Go deeper on propofol + valproate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on propofol + valproate.